These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 25764482

  • 1. Vision-Related Quality-of-Life Outcomes in the Mycotic Ulcer Treatment Trial I: A Randomized Clinical Trial.
    Rose-Nussbaumer J, Prajna NV, Krishnan KT, Mascarenhas J, Rajaraman R, Srinivasan M, Raghavan A, Oldenburg CE, O'Brien KS, Ray KJ, McLeod SD, Porco TC, Lietman TM, Acharya NR, Keenan JD, Mycotic Ulcer Treatment Trial I Group.
    JAMA Ophthalmol; 2015 Jun; 133(6):642-6. PubMed ID: 25764482
    [Abstract] [Full Text] [Related]

  • 2. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole.
    Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, Raghavan A, Oldenburg CE, Ray KJ, Zegans ME, McLeod SD, Porco TC, Acharya NR, Lietman TM, Mycotic Ulcer Treatment Trial Group.
    JAMA Ophthalmol; 2013 Apr; 131(4):422-9. PubMed ID: 23710492
    [Abstract] [Full Text] [Related]

  • 3. Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.
    Prajna NV, Lalitha P, Rajaraman R, Krishnan T, Raghavan A, Srinivasan M, O'Brien KS, Zegans M, McLeod SD, Acharya NR, Keenan JD, Lietman TM, Rose-Nussbaumer J, Mycotic Ulcer Treatment Trial Group.
    JAMA Ophthalmol; 2016 Jun 01; 134(6):693-6. PubMed ID: 27054515
    [Abstract] [Full Text] [Related]

  • 4. Adjunctive Oral Voriconazole Treatment of Fusarium Keratitis: A Secondary Analysis From the Mycotic Ulcer Treatment Trial II.
    Prajna NV, Krishnan T, Rajaraman R, Patel S, Shah R, Srinivasan M, Devi L, Das M, Ray KJ, O'Brien KS, Oldenburg CE, McLeod SD, Zegans ME, Acharya NR, Lietman TM, Rose-Nussbaumer J, Mycotic Ulcer Treatment Trial Group.
    JAMA Ophthalmol; 2017 Jun 01; 135(6):520-525. PubMed ID: 28426856
    [Abstract] [Full Text] [Related]

  • 5. Comparison of natamycin and voriconazole for the treatment of fungal keratitis.
    Prajna NV, Mascarenhas J, Krishnan T, Reddy PR, Prajna L, Srinivasan M, Vaitilingam CM, Hong KC, Lee SM, McLeod SD, Zegans ME, Porco TC, Lietman TM, Acharya NR.
    Arch Ophthalmol; 2010 Jun 01; 128(6):672-8. PubMed ID: 20547942
    [Abstract] [Full Text] [Related]

  • 6. Predictors of Corneal Perforation or Need for Therapeutic Keratoplasty in Severe Fungal Keratitis: A Secondary Analysis of the Mycotic Ulcer Treatment Trial II.
    Prajna NV, Krishnan T, Rajaraman R, Patel S, Shah R, Srinivasan M, Das M, Ray KJ, Oldenburg CE, McLeod SD, Zegans ME, Acharya NR, Lietman TM, Rose-Nussbaumer J, Mycotic Ulcer Treatment Trial Group.
    JAMA Ophthalmol; 2017 Sep 01; 135(9):987-991. PubMed ID: 28817744
    [Abstract] [Full Text] [Related]

  • 7. Risk factors for low vision related functioning in the Mycotic Ulcer Treatment Trial: a randomised trial comparing natamycin with voriconazole.
    Rose-Nussbaumer J, Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Srinivasan M, Raghavan A, Oldenburg CE, O'Brien KS, Ray KJ, Porco TC, McLeod SD, Acharya NR, Keenan JD, Lietman TM, Mycotic Ulcer Treatment Trial Group.
    Br J Ophthalmol; 2016 Jul 01; 100(7):929-932. PubMed ID: 26531051
    [Abstract] [Full Text] [Related]

  • 8. Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial.
    Prajna NV, Krishnan T, Rajaraman R, Patel S, Srinivasan M, Das M, Ray KJ, O'Brien KS, Oldenburg CE, McLeod SD, Zegans ME, Porco TC, Acharya NR, Lietman TM, Rose-Nussbaumer J, Mycotic Ulcer Treatment Trial II Group.
    JAMA Ophthalmol; 2016 Dec 01; 134(12):1365-1372. PubMed ID: 27787540
    [Abstract] [Full Text] [Related]

  • 9. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers.
    Arora R, Gupta D, Goyal J, Kaur R.
    Clin Exp Ophthalmol; 2011 Jul 01; 39(5):434-40. PubMed ID: 21105974
    [Abstract] [Full Text] [Related]

  • 10. Patterns of Antifungal Resistance in Adult Patients With Fungal Keratitis in South India: A Post Hoc Analysis of 3 Randomized Clinical Trials.
    Prajna NV, Lalitha P, Krishnan T, Rajaraman R, Radnakrishnan N, Srinivasan M, Devi L, Das M, Liu Z, Zegans ME, Acharya NR, Porco TC, Lietman TM, Rose-Nussbaumer J.
    JAMA Ophthalmol; 2022 Feb 01; 140(2):179-184. PubMed ID: 35024776
    [Abstract] [Full Text] [Related]

  • 11. Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.
    Sun CQ, Lalitha P, Prajna NV, Karpagam R, Geetha M, O'Brien KS, Oldenburg CE, Ray KJ, McLeod SD, Acharya NR, Lietman TM, Mycotic Ulcer Treatment Trial Group.
    Ophthalmology; 2014 Aug 01; 121(8):1495-500.e1. PubMed ID: 24746358
    [Abstract] [Full Text] [Related]

  • 12. The Prognostic Value of Persistent Culture Positivity in Fungal Keratitis in the Mycotic Antimicrobial Localized Injection Trial.
    Pickel J, Narayana S, Krishnan T, Ramakrishnan S, Samantaray PP, Porco TC, Redd T, Lietman TM, Rose-Nussbaumer J.
    Am J Ophthalmol; 2020 Jul 01; 215():1-7. PubMed ID: 32171765
    [Abstract] [Full Text] [Related]

  • 13. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial.
    Sharma S, Das S, Virdi A, Fernandes M, Sahu SK, Kumar Koday N, Ali MH, Garg P, Motukupally SR.
    Br J Ophthalmol; 2015 Sep 01; 99(9):1190-5. PubMed ID: 25740805
    [Abstract] [Full Text] [Related]

  • 14. In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.
    Lalitha P, Sun CQ, Prajna NV, Karpagam R, Geetha M, O'Brien KS, Cevallos V, McLeod SD, Acharya NR, Lietman TM, Mycotic Ulcer Treatment Trial Group.
    Am J Ophthalmol; 2014 Feb 01; 157(2):318-26. PubMed ID: 24439440
    [Abstract] [Full Text] [Related]

  • 15. Mycotic Antimicrobial Localized Injection: A Randomized Clinical Trial Evaluating Intrastromal Injection of Voriconazole.
    Narayana S, Krishnan T, Ramakrishnan S, Samantaray PP, Austin A, Pickel J, Porco T, Lietman T, Rose-Nussbaumer J.
    Ophthalmology; 2019 Aug 01; 126(8):1084-1089. PubMed ID: 30904540
    [Abstract] [Full Text] [Related]

  • 16. Topical Chlorhexidine 0.2% versus Topical Natamycin 5% for the Treatment of Fungal Keratitis in Nepal: A Randomized Controlled Noninferiority Trial.
    Hoffman JJ, Yadav R, Sanyam SD, Chaudhary P, Roshan A, Singh SK, Singh SK, Mishra SK, Arunga S, Hu VH, Macleod D, Leck A, Burton MJ.
    Ophthalmology; 2022 May 01; 129(5):530-541. PubMed ID: 34896126
    [Abstract] [Full Text] [Related]

  • 17. Medical interventions for fungal keratitis.
    FlorCruz NV, Evans JR.
    Cochrane Database Syst Rev; 2015 Apr 09; 2015(4):CD004241. PubMed ID: 25855311
    [Abstract] [Full Text] [Related]

  • 18. Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial.
    Lalitha P, Prajna NV, Oldenburg CE, Srinivasan M, Krishnan T, Mascarenhas J, Vaitilingam CM, McLeod SD, Zegans ME, Porco TC, Acharya NR, Lietman TM.
    Cornea; 2012 Jun 09; 31(6):662-7. PubMed ID: 22333662
    [Abstract] [Full Text] [Related]

  • 19. Regression Discontinuity and Randomized Controlled Trial Estimates: An Application to The Mycotic Ulcer Treatment Trials.
    Oldenburg CE, Venkatesh Prajna N, Krishnan T, Rajaraman R, Srinivasan M, Ray KJ, O'Brien KS, Glymour MM, Porco TC, Acharya NR, Rose-Nussbaumer J, Lietman TM.
    Ophthalmic Epidemiol; 2018 Aug 09; 25(4):315-322. PubMed ID: 29718751
    [Abstract] [Full Text] [Related]

  • 20. Effect of pretreatment with antifungal agents on clinical outcomes in fungal keratitis.
    Sun CQ, Prajna NV, Krishnan T, Rajaraman R, Srinivasan M, Raghavan A, O'Brien KS, McLeod SD, Acharya NR, Rose-Nussbaumer J, Mycotic Ulcer Treatment Trial Group.
    Clin Exp Ophthalmol; 2016 Dec 09; 44(9):763-767. PubMed ID: 27329780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.